Pulmonary Hypertension

Phase 3 Data Points to Treprostinil as a Treatment for Pulmonary Hypertension - MD Magazine Phase 3 Data Points to Treprostinil as a Treatment for Pulmonary Hypertension - MD Magazine Posted: 25 Jun 2020 07:25 AM PDT Steven D. Nathan, MD In a study testing treprostinil (Tyvaso) as a potential treatment for pulmonary hypertension , investigators have reached all intended primary and secondary endpoints. On June 17, the United Therapeutics Corporation announced positive data from the INCREASE study showing treprostinil inhalation solution is effective treating patients with pulmonary hypertension associated with interstitial lung disease. In the phase 3, multicenter, randomized, double-blinded, placebo-controlled, 16-week, parallel group study, the investigators examined 326 patients who received either the study drug or a placebo.  The data was presented virtually at the American Thoracic Society (ATS) 2020 Virtual Sessions this wee...

Congenital Heart Disease-Associated PAH vs Idiopathic PAH Survival Rates - Pulmonology Advisor Congenital Heart Disease-Associated PAH vs Idiopathic PAH Survival Rates - Pulmonology Advisor Posted: 11 Jun 2020 12:00 AM PDT The overall survival in individuals with congenital heart disease-associated pulmonary hypertension (PH) depends on their underlying diagnosis and treatment status, but has been shown to be significantly better than the overall survival in those with idiopathic pulmonary arterial hypertension (PAH). A subgroup of patients from the international Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) with PH related to congenital heart disease (COMPERA-CHD) were analyzed. Results of the study were published in the Journal of Clinical Medicine . Investigators sought to describe current management strategies and outcomes in adults with PH relative to different types of congenita...

Pulmonary Arterial Hypertension (PAH) Market Size & Share Analysis by Actelion Pharmaceuticals Ltd, DAIICHI SANKYO COMPANY, LIMITED, GlaxoSmithKline plc - Jewish Life News Pulmonary Arterial Hypertension (PAH) Market Size & Share Analysis by Actelion Pharmaceuticals Ltd, DAIICHI SANKYO COMPANY, LIMITED, GlaxoSmithKline plc - Jewish Life News Posted: 23 Jun 2020 05:22 AM PDT Global Pulmonary Arterial Hypertension (PAH) Market  By Drug Type (Endothelin Receptor Antagonists (ERAs), Vasodilators, Phosphodiesterase-5 inhibitors, Soluble Guanylate Cyclase Stimulators, Calcium Channel Blockers, Prostacyclin & prostacyclin analogs, Others), Route of administration (Inhalation, Injectable, Oral administration), End-users (Hospitals, Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East, and Africa) – Industry Trends & Forecast to 2026 The major competitors currently working in the pulmonary a...

Beyond Air Reports Financial Results for Fiscal Fourth Quarter and Year-End 2020 - GlobeNewswire Beyond Air Reports Financial Results for Fiscal Fourth Quarter and Year-End 2020 - GlobeNewswire Posted: 22 Jun 2020 01:14 PM PDT Reported positive clinical data for third bronchiolitis study using high concentration nitric oxide, achieving primary and key secondary endpoints Enrolled first patient in the U.S. COVID-19 study using the LungFit ™ system Announced positive pre-clinical data validating high concentration nitric oxide as a potential treatment for ablating solid tumors and inducing an anti-tumor immune response PMA for the LungFit™ PH to treat persistent pulmonary hypertension of the newborn (PPHN) expected to be submitted to the FDA in the second half of 2020 LungFit ™ You are subscribed to email updates from "pulmonary hypertension treatment" - Google News . To stop receiving these emails, you ma...

Tiny RNA Molecule, MicroRNA-483, May Help Ease PAH, Early Study Finds - Pulmonary Hypertension News Tiny RNA Molecule, MicroRNA-483, May Help Ease PAH, Early Study Finds - Pulmonary Hypertension News Posted: 22 Jun 2020 08:00 AM PDT Increasing the levels of a tiny  RNA molecule  known as microRNA-483 enhanced the function of  endothelial cells and eased the symptoms of pulmonary arterial hypertension  (PAH) in rat models of the disease, a new study shows. The results support the potential of microRNA-483 as a potential therapy for PAH. The study, " MicroRNA-483 amelioration of experimental pulmonary hypertension , " was published in the journal EMBO Molecular Medicine . The improper functioning of endothelial cells — those lining the inner wall of blood vessels – is characteristic of PAH progression. Compromised endothelial cells produce higher-than-normal levels of pro-inflammatory molecule...

Pulmonary Arterial Hypertension (PAH) Market Is Thriving Worldwide By 2026 | Actelion Pharmaceuticals Ltd, DAIICHI SANKYO COMPANY, LIMITED, GlaxoSmithKline plc, Novartis AG, United Therapeutics Corporation - Cole of Duty Pulmonary Arterial Hypertension (PAH) Market Is Thriving Worldwide By 2026 | Actelion Pharmaceuticals Ltd, DAIICHI SANKYO COMPANY, LIMITED, GlaxoSmithKline plc, Novartis AG, United Therapeutics Corporation - Cole of Duty Posted: 15 Jun 2020 10:14 AM PDT Global Pulmonary Arterial Hypertension Market is expected to rise gradually to an estimated value of USD 9.13 billion by 2026, registering a CAGR of 5.5% in the forecast period of 2019-2026 with the annual sales of USD 5.95 billion in the year 2018.  This rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients. Global Pulmonary Arterial Hypertension (PAH) Market By Drug Type (Endothelin Receptor Antagonists (ERAs), Va...

Nicotine Inhaled Often, as with E-cigarette Use, Linked to PH in Mice - Pulmonary Hypertension News Nicotine Inhaled Often, as with E-cigarette Use, Linked to PH in Mice - Pulmonary Hypertension News Posted: 22 May 2020 12:00 AM PDT Chronic inhalation of nicotine , the addictive component of all tobacco products, is enough to trigger changes in pulmonary arteries and in the heart's right chamber that can cause pulmonary hypertension (PH), a recent study in mice found. The study, " Effects of Chronic Nicotine Inhalation on Systemic and Pulmonary Blood Pressure and Right Ventricular Remodeling in Mice ," was published in the journal Hypertension . Pulmonary hypertension is a chronic and progressive disease in which the pulmonary arteries become narrowed and blocked, requiring the heart to pump harder for blood to flow through these blood vessels. This extra effort can enlarge and weaken the ...